Leiden Dworak - Aug 14, 2025 Form 3 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Principal Accounting Officer
Signature
/s/ Zoran Zdraveski, Attorney-in-Fact
Stock symbol
TCRX
Transactions as of
Aug 14, 2025
Transactions value $
$0
Form type
3
Date filed
8/22/2025, 04:10 PM
Previous filing
Feb 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dworak Leiden Principal Accounting Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM /s/ Zoran Zdraveski, Attorney-in-Fact 2025-08-22 0001986012

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 37.5K $2.90 Direct F1
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 23.8K $1.81 Direct F2
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 164K $2.49 Direct F3
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 25K $2.23 Direct F4
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 46.9K $6.00 Direct F5
holding TCRX Stock Option (Right to Buy) Aug 14, 2025 Voting Common Stock 70K $3.07 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 4, 2022, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F2 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of February 2, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F3 96,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 67,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.
F4 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of July 21, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F5 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F6 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney